These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor]. Streifler M; Vardi J; Kesten M Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737 [No Abstract] [Full Text] [Related]
46. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism]. Gattringer B; Steinhäusl H Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132 [No Abstract] [Full Text] [Related]
47. Preliminary observations on L-dopa in the treatment of Parkinson's disease. Jelsma F; Roth R; Ross P; Davis J J Ky Med Assoc; 1971 Apr; 69(4):265-9. PubMed ID: 5577419 [No Abstract] [Full Text] [Related]
48. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Rinne UK; Sonninen V; Sirtola T Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458 [No Abstract] [Full Text] [Related]
49. [Mental disorders in the course of L-dopa treatment]. Reichowa J; Goldsztajn M Psychiatr Pol; 1973; 7(1):87-9. PubMed ID: 4715838 [No Abstract] [Full Text] [Related]
50. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970 [No Abstract] [Full Text] [Related]
51. Therapeutic uses and side effects of L-dopa. Boshes B Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081 [No Abstract] [Full Text] [Related]
52. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa]. Almici GM; Sbarbaro V Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722 [No Abstract] [Full Text] [Related]
53. [Current treatment of Parkinson syndrome with L-dopa]. Gerstendbrand F; Gründig E; Musiol A Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002 [No Abstract] [Full Text] [Related]
55. Experimental evaluation of L-dopa penetration in brain. De la Torre JC; Mullan S Trans Am Neurol Assoc; 1971; 96():227-9. PubMed ID: 5159088 [No Abstract] [Full Text] [Related]
56. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study]. Wälzholz U; Schönfelder H Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192 [No Abstract] [Full Text] [Related]
57. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor]. Christiani K; Möller WD Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759 [No Abstract] [Full Text] [Related]
58. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease]. Buscaino GA; Campanella G Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561 [No Abstract] [Full Text] [Related]
59. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)]. Eisenlohr JJ; Gehlen W MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699 [No Abstract] [Full Text] [Related]
60. [Dopa and decarboxylase inhibitors in Parkinson's disease]. Pakkenberg H Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]